Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
March 31, 2021
March 31, 2021
March 10, 2021
March 10, 2021
February 3, 2021
January 15, 2021
January 13, 2021
January 12, 2021
January 11, 2021
January 11, 2021
January 7, 2021